purpos
studi
investig
outcom
antimicrobi
deescal
ade
base
mortal
incid
multidrug
resist
mdr
pathogen
occurr
patient
cultureneg
pneumonia
present
sepsi
septic
shock
materi
method
retrospect
analyz
patient
diagnos
sever
pneumonia
requir
intens
care
unit
icu
admiss
possess
neg
microbiolog
cultur
result
tertiari
referr
hospit
south
korea
march
juli
result
identifi
patient
cultureneg
pneumonia
acut
physiolog
chronic
health
evalu
apach
ii
sepsisrel
organ
failur
assess
sofa
mean
score
respect
among
patient
underw
ade
apach
ii
sofa
followup
sofa
score
differ
significantli
group
differ
found
icu
mortal
mdr
pathogen
occurr
vs
p
vs
p
respect
conclus
observ
similar
icu
mortal
mdr
pathogen
occurr
patient
cultureneg
pneumonia
present
sepsisshock
regardless
whether
receiv
ade
addit
ade
lower
antimicrobi
burden
although
incid
mortal
sepsi
septic
shock
vari
across
region
incid
condit
show
increas
trend
pose
major
public
health
burden
worldwid
pneumonia
lead
caus
sepsi
critic
ill
patient
hospit
intens
care
unit
icu
current
guidelin
sepsi
septic
shock
manag
recommend
empir
administr
broadspectrum
antibiot
initi
therapi
deescal
narrowspectrum
antibiot
patient
respond
previou
studi
attempt
show
relationship
antimicrobi
deescal
ade
multidrugresist
mdr
pathogen
occurr
unabl
demonstr
consist
result
although
pneumonia
cultureneg
pneumonia
specif
target
previou
investig
appropri
empir
antimicrobi
therapi
consist
shown
independ
factor
relat
ade
mortal
patient
receiv
ade
found
inferior
howev
effect
ade
patient
sepsi
septic
shock
undocu
etiolog
pathogen
unclear
despit
improv
diagnost
modal
rate
posit
microbiolog
cultur
approxim
patient
sever
sepsi
moreov
mortal
relat
pathogen
identif
therefor
investig
impact
ade
patient
cultureneg
pneumonia
present
sepsi
septic
shock
requir
icu
admiss
focus
icu
inhospit
mortal
emerg
mdr
pathogen
retrospect
studi
conduct
medic
icu
asan
medic
center
referr
hospit
seoul
korea
sinc
rapid
respons
team
rrt
whose
goal
earli
recognit
treatment
sepsi
oper
hospit
team
result
establish
rrt
registri
septic
patient
retrospect
review
registri
march
juli
among
patient
met
registri
criteria
screen
diagnos
sepsi
septic
shock
due
pneumonia
requir
icu
admiss
regardless
clinic
set
ie
communityacquir
hospitalacquir
subsequ
patient
cultureneg
pneumonia
includ
patient
exclud
base
follow
criteria
case
etiolog
agent
identifi
admiss
icu
day
ii
patient
die
within
day
icu
admiss
iii
case
patient
immunocompromis
hematolog
malign
organ
transplant
recipi
receiv
immun
suppress
treat
connect
tissu
diseas
iv
patient
noninfecti
caus
asthma
chronic
obstruct
pulmonari
diseas
interstiti
lung
diseas
v
patient
younger
year
first
admiss
patient
includ
detail
evalu
use
strobe
checklist
studi
protocol
approv
institut
review
board
asan
medic
center
irb
waiv
requir
inform
consent
due
retrospect
natur
analysi
current
studi
defin
septic
patient
accord
definit
sepsi
accord
guidelin
sequenti
organ
failur
assess
sofa
score
calcul
patient
elig
evalu
pivot
antibiot
consist
carbapenem
antipseudomon
antibiot
inhibitor
gener
cephalosporin
ceftazidim
gener
cephalosporin
exclud
ceftazidim
glycopeptid
aminopenicillin
companion
antibiot
consist
fluoroquinolon
macrolid
tetracyclin
defin
ade
discontinu
pivot
companion
antibiot
switch
pivot
antibiot
icu
day
follow
carbapenem
replac
anoth
class
pivot
antibiot
antipseudomon
antibiot
chang
without
antipseudomon
effect
defin
antibiot
burden
first
day
product
treatment
durat
number
antibiot
patient
die
transfer
gener
ward
within
day
burden
antibiot
calcul
day
death
transfer
icu
mortal
defin
death
treatment
icu
within
one
day
transfer
gener
ward
termin
care
inhospit
mortal
defin
death
hospit
stay
categor
caus
death
either
pneumoniarel
pneumoniaunrel
primari
outcom
icu
mortal
secondari
outcom
inhospit
mortal
occurr
rate
mdr
pathogen
acut
physiolog
chronic
health
evalu
apach
ii
sofa
score
evalu
date
icu
admiss
sofa
score
reassess
day
antimicrobi
deescal
ade
group
icu
day
nonad
group
also
calcul
score
initi
sofa
scorefollowup
sofa
score
addit
evalu
underli
medic
condit
ie
diabet
mellitu
chronic
liver
kidney
diseas
congest
heart
failur
durat
antimicrobi
treatment
prior
icu
admiss
evalu
occurr
mdr
pathogen
sampl
stool
cultur
toxin
assay
collect
clostridium
difficil
sampl
microbiolog
cultur
collect
test
methicillinresist
staphylococcu
aureu
mrsa
carbapenemresist
acinetobact
baumannii
crab
carbapenemresist
pseudomona
aeruginosa
crpa
posit
cultur
establish
etiolog
agent
identifi
blood
sputum
endotrach
aspir
bronchoalveolar
lavag
fluid
also
consid
posit
test
cultureposit
reversetranscript
polymeras
chain
reaction
rtpcr
respiratori
virus
pcr
mycoplasma
pneumonia
chlamydophila
pneumonia
urinari
antigen
test
pneumococcu
binax
inc
portland
usa
legionella
serogroup
binax
inc
rtpcr
assay
detect
influenza
virus
b
adenoviru
bocaviru
coronaviru
coronaviru
enteroviru
human
metapneumoviru
parainfluenza
virus
seegen
inc
seoul
republ
korea
consid
case
cultureneg
test
neg
day
icu
admiss
icu
day
surveil
mrsa
carbapenemresist
pathogen
patient
admit
icu
underw
nasal
swab
cultur
mrsa
sputum
endotrach
aspir
cultur
time
icu
admiss
everi
week
thereaft
day
icu
discharg
analys
perform
use
spss
statist
softwar
version
ibm
corp
armonk
ny
usa
student
ttest
mannwhitney
u
test
use
continu
variabl
fisher
exact
test
use
categor
variabl
test
signific
twosid
p
valu
consid
statist
signific
elig
screen
identifi
patient
admit
icu
diagnosi
sepsi
septic
shock
due
pneumonia
whose
microbiolog
cultur
test
neg
fig
patient
pneumonia
patient
diagnos
communityacquir
pneumonia
remain
patient
diagnos
hospitalacquir
pneumonia
averag
age
year
preponder
male
patient
approxim
patient
requir
mechan
ventil
time
rrt
activ
mean
apach
ii
sofa
score
respect
median
durat
antibiot
treatment
icu
admiss
day
interquartil
rang
iqr
median
length
gener
ward
stay
day
iqr
among
patient
ade
perform
patient
baselin
characterist
shown
tabl
total
patient
receiv
two
antibiot
icu
admiss
common
antibiot
combin
carbapenem
glycopeptid
fluoroquinolon
differ
found
type
antibiot
administ
two
group
ade
group
glycopeptid
common
deescal
antimicrobi
agent
follow
carbapenem
tabl
median
time
day
admiss
day
deescal
ade
group
three
day
iqr
averag
followup
sofa
score
ade
group
nonad
group
signific
differ
found
followup
sofa
score
two
group
icu
mortal
ade
group
nonad
group
p
tabl
mean
icu
length
stay
similar
ade
day
iqr
nonad
group
day
iqr
p
multivari
analysi
ade
significantli
associ
reduc
mortal
hazard
ratio
confid
interv
p
tabl
patient
transfer
gener
ward
patient
ade
patient
nonad
group
die
hospit
mortal
similar
ade
nonad
group
p
tabl
differ
note
clinic
characterist
caus
death
two
group
data
shown
antibiot
burden
significantli
lower
ade
group
nonad
group
p
antibiot
durat
day
patient
day
icu
stay
three
patient
antibioticfre
day
aliv
wherea
patient
antibioticfre
day
die
microbi
cultur
patient
identifi
multidrug
resist
pathogen
icu
hospit
crab
crpa
identifi
patient
mrsa
identifi
patient
one
patient
crab
mrsa
superinfect
document
clostridium
difficil
infect
cdi
identifi
case
differ
observ
ade
nonad
group
p
tabl
evid
suggest
appropri
antimicrobi
choic
may
reduc
mortal
likelihood
mdr
pathogen
occurr
critic
ill
patient
sepsi
septic
shock
current
guidelin
recommend
empir
antibiot
chang
narrow
spectrum
etiolog
agent
document
howev
research
effect
deescal
stewardship
case
cultureneg
sepsi
limit
best
knowledg
studi
first
evalu
rel
larg
number
patient
sever
pneumonia
whose
microbiolog
identif
test
includ
multiplexpcr
urinari
antigen
test
could
posit
identifi
specif
pathogen
found
differ
icu
mortal
mdr
pathogen
emerg
ade
nonad
patient
howev
inhospit
mortal
tend
better
ade
group
find
suggest
ade
consid
microbiolog
identif
test
neg
icu
patient
pneumonia
previou
observ
studi
describ
effect
ade
mortal
limit
draw
conclus
ade
could
safe
perform
cultureneg
sepsi
septic
shock
patient
pneumonia
limit
includ
small
number
cultureneg
patient
pneumonia
ade
inclus
patient
admit
icu
reason
pneumonia
admiss
surgic
icu
risk
factor
polymicrobi
infect
recent
first
random
control
trial
ade
reveal
mortal
rate
differ
ade
antimicrobi
continu
group
septic
patient
includ
caus
urinari
tract
intraabdomin
infect
primari
outcom
measur
base
patient
studi
subgroup
analysi
patient
pneumonia
icu
stay
superinfect
episod
differ
ade
nonad
group
given
antibiot
streamlin
determin
combin
microbiolog
cultur
result
infect
sourc
patient
clinic
cours
effect
sourc
control
chose
focu
patient
cultureneg
sepsi
septic
shock
due
pneumonia
studi
exclud
patient
posit
test
viral
pneumonia
sinc
mortal
viral
pneumonia
significantli
differ
bacteri
pneumonia
decis
pursu
deescal
may
mean
clinic
symptom
improv
serial
sofa
score
sever
measur
assess
use
determin
whether
ade
perform
safe
howev
found
initi
apach
ii
sofa
score
similar
two
group
score
ade
group
tend
less
improv
although
significantli
nonad
group
find
suggest
ade
safe
perform
clinic
paramet
deterior
icu
day
inde
followup
sofa
score
independ
risk
factor
icu
mortal
multivari
analysi
p
b
nonetheless
unmeasur
clinic
factor
detect
apach
sofa
score
may
determin
whether
ade
perform
relationship
prolong
antimicrobi
treatment
emerg
mdr
pathogen
remain
unclear
incid
mdr
pathogen
studi
compar
publish
studi
common
deescal
antibiot
glycopeptid
follow
carbapenem
reflect
concern
emerg
pathogen
resist
class
antibiot
notabl
subgroup
analysi
found
correl
carbapenem
discontinu
emerg
crab
crpa
tabl
onlin
supplement
file
carlier
colleagu
report
probabl
reach
target
pharmacokinet
pk
pharmacodynam
pd
narrowspectrum
antibiot
less
broadspectrum
agent
although
longer
durat
therapi
would
contribut
increas
risk
mdr
pathogen
emerg
reach
pk
pd
target
could
indic
insuffici
drug
administ
obtain
therapeut
respons
light
patient
receiv
ade
may
like
longer
durat
antimicrobi
therapi
thu
increas
incid
mdr
pathogen
although
evalu
pk
pd
antimicrobi
agent
durat
antibiot
differ
ade
nonad
group
studi
larg
number
patient
warrant
evalu
relationship
ade
mdr
pathogen
emerg
current
studi
sever
limit
first
studi
conduct
singl
center
design
retrospect
thu
find
current
studi
may
applic
patient
cultureneg
pneumonia
addit
although
conduct
meticul
surveil
cultur
diagnost
test
patient
clinic
deterior
due
noninfecti
caus
may
includ
second
consensu
definit
ade
make
comparison
studi
use
differ
conflict
definit
difficult
third
serial
procalcitonin
check
patient
thu
procalcitoninguid
antimicrobi
stewardship
could
evalu
studi
howev
among
patient
followup
procalcitonin
data
associ
found
procalcitonin
antimicrobi
deescal
tabl
onlin
supplement
file
fourth
inform
rrt
registri
consist
patient
suspect
sepsi
alreadi
receiv
antibiot
therapi
fifth
sinc
studi
durat
year
time
effect
result
might
occur
howev
perform
analysi
two
group
accord
time
period
signific
differ
observ
effect
ade
icu
mortal
tabl
onlin
supplement
file
lastli
import
limit
current
studi
antimicrobi
stewardship
protocol
exist
timefram
absenc
antimicrobi
protocol
led
excess
treatment
durat
subject
strongli
deviat
current
guidelin
addit
differ
mortal
found
day
n
day
antibiot
use
thu
although
studi
show
safeti
ade
patient
cultureneg
pneumonia
also
indic
import
earli
discontinu
antibiot
patient
conclus
found
icu
mortal
occurr
mdr
superinfect
higher
patient
receiv
ade
continu
receiv
broadspectrum
therapi
addit
patient
underw
ade
show
lower
burden
antimicrobi
agent
find
suggest
ade
still
consid
patient
cultureneg
pneumonia
present
sepsi
septic
shock
continu
neg
icu
day
research
receiv
specif
grant
fund
agenc
public
commerci
notforprofit
sector
none
